Evidence map›Paper›PMID 27900641›Full record

ReviewJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology2017

Cardiovascular PET/MR: We need evidence, not hype.

Afshin Farzaneh-Far, Raymond Y Kwong

Abstract readEditorialReview
PubMed Publisher
In one paragraph

Review in Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Cardiovascular PET/MR: "Not the end but the beginning".Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Afshin Farzaneh-FarDivision of Cardiology, Department of Medicine, University of Illinois at Chicago, Chicago, IL, USA.
Raymond Y KwongCardiovascular Division, Department of Medicine, Brigham and Women's Hospital, 75 Francis Street, Boston, MA, 02115, USA. rykwong@partners.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent introduction of hybrid positron emission tomography/magnetic resonance (PET/MR) scanners has created excitement regarding potential applications in cardiovascular medicine. This has led to a number of optimistic assessments of its potential value in the nuclear cardiology literature, although most published data are still at the feasibility or pre-clinical level. Such excitement is understandable and provides "fuel" for generation of the necessary clinical validation studies, which will be required. Given the current scrutiny from payers and government agencies to reduce the costs of cardiac imaging, the responsibility for showing additive benefit lies on the shoulders of those advocating for new, more expensive technologies. In the case of PET/MR, this will be a major challenge, given the high costs of the hybrid procedure and the need for potentially harmful ionizing radiation compared to a cardiac magnetic resonance (CMR)-only approach. The aim of this editorial is to provide a critical appraisal of the current evidence base for clinical use of PET/MR in cardiology.

Indexed as

Cardiac Imaging TechniquesEvidence-Based MedicineForecastingHeart DiseasesHumansMagnetic Resonance ImagingMolecular ImagingMultimodal ImagingPositron-Emission TomographyReproducibility of ResultsSensitivity and SpecificityMagnetic resonance imagingMyocardial perfusion imaging: PETMyocardial perfusion imaging: SPECTMyocardial viabilityMyocarditis

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.